<DOC>
	<DOCNO>NCT00740389</DOCNO>
	<brief_summary>This Phase I , open-label , 3-period crossover trial investigate pharmacokinetic interaction ( process drug absorb , distribute , metabolise eliminate body ) TMC125 fluconazole , TMC125 voriconazole .</brief_summary>
	<brief_title>TMC125-TiDP2-C187 : A Phase I , Open-label Trial Investigate Pharmacokinetic Interaction Between TMC125 Two Antifungal Agents ( Fluconazole Voriconazole ) , All Steady-state Healthy Subjects .</brief_title>
	<detailed_description>In Phase I , open-label , 3-period crossover trial potential pharmacokinetic interaction TMC125 fluconazole TMC125 voriconazole investigate . Fluconazole voriconazole triazole antifungal agent . Fluconazole voriconazole inhibitor CYP isoenzymes 2C19 , 2C9 CYP3A4 . Fluconazole metabolize liver small extent . Approximately 80 % administered fluconazole dose appear urine unchanged form . Voriconazole metabolize CYP2C19 , 2C9 3A4 . TMC125 also metabolize CYP3A , 2C9 2C19 . Because effect fluconazole voriconazole metabolic pathways relevant TMC125 metabolism , concomitant administration TMC125 fluconazole voriconazole might increase TMC125 pharmacokinetics . Because effect TMC125 metabolic pathway relevant voriconazole metabolism , concomitant administration TMC125 voriconazole might also modify voriconazole pharmacokinetics . Since elimination fluconazole mainly via kidney , effect TMC125 fluconazole pharmacokinetics expect . The current trial aim ass 2-way pharmacokinetic interaction TMC125 fluconazole , TMC125 voriconazole , provide dose recommendation combine use treatment HIV infect patients.In trial pharmacokinetic interaction TMC125 fluconazole , TMC125 voriconazole , steady-state investigate 18 healthy subject . During first two session , subject receive 2 treatment ( Treatments A B ) randomize way . In Treatment A , 200 mg TMC125 twice day . administer Day 1 Day 7 additional morning dose Day 8 . In Treatment B , 200 mg fluconazole day morning administer Day 1 Day 16 , co-administered 200 mg TMC125 twice day Day 9 Day 16 . These session follow third session , Treatment C , 400 mg voriconazole twice day administer Day 1 200 mg voriconazole twice day administer Day 2 Day 15 , additional morning dose Day 16 . From Day 9 Day 15 , 200 mg TMC125 twice day co-administered , additional morning dose Day 16 . All TMC125 fluconazole intake feed condition , within 10 minute meal . Voriconazole administer 1.5 hour meal . Between subsequent treatment session , washout period least 2 week . Full pharmacokinetic profile determine one dose interval ( 12 hour ) TMC125 Day 8 Treatment A Day 16 Treatments B C. For fluconazole , full pharmacokinetic profile determine one dose interval ( 24 hour ) Days 8 16 Treatment B . For voriconazole , full pharmacokinetic profile determine one dose interval ( 12 hour ) Days 8 16 Treatment C. Safety tolerability monitor continuously throughout trial . Treatment A : 200 mg TMC125 twice daily , orally Day 1 7 morning dose Day 8 . Treatment B : 200 mg fluconazole daily , orally Day 1 16 , co-administered 200 mg TMC125 twice daily Day 9 16 . Treatment C : 400 mg voriconazole twice daily , orally Day 1 200 mg voriconazole twice daily administer Day 2 15 , morning dose Day 16 . From Day 9 15 , 200 mg TMC125 twice daily co-administered , morning dose Day 16 .</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<mesh_term>Antifungal Agents</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<mesh_term>Etravirine</mesh_term>
	<criteria>Nonsmoking smoke 10 cigarette , 2 cigar , 2 pipe per day least 3 month prior screen Body Mass Index ( BMI ) 18.0 30.0 kg/m2 , extremes include . BMI calculate weight ( kg ) divide square height ( ) Informed Consent Forms sign voluntarily first trialrelated activity Able comply protocol requirement Healthy basis medical evaluation reveals absence clinically relevant abnormality include physical examination ( include skin examination ) , medical surgical history , electrocardiogram ( ECG ) , vital sign result blood biochemistry , hematology urinalysis carry Screening . A positive HIV1 HIV2 test study screen Female , except postmenopausal since two year , posthysterectomy surgically sterilize ( without reversal operation ) History evidence current use alcohol , barbiturate , amphetamine , recreational narcotic drug use investigator 's opinion would compromise subject 's safety and/or compliance study procedure Hepatitis A infection , hepatitis B infection , hepatitis C infection study screen A positive urine drug test study screen Day 1 session . Urine test presence amphetamine , benzodiazepine , cocaine , cannabinoids opioids Currently active underlie gastrointestinal , cardiovascular , neurologic , psychiatric , metabolic , renal , hepatic , respiratory , inflammatory infectious disease Currently significant diarrhea , gastric stasis constipation investigator 's opinion could influence drug absorption bioavailability Any history significant skin disease . Previously demonstrate clinically significant allergy hypersensitivity fluconazole , voriconazole and/or excipients investigational medication administer trial Clinical evidence history long QT syndrome history additional risk factor Torsade de Pointes , cardiomyopathy , heart failure , hypokalemia , family history know Long QT Syndrome , sudden unexplained death young age ( = 40 year ) firstdegree relative ( i.e. , biological parent , sibling , offspring ) Clinically relevant heart rhythm disturbance know suggested history , 12lead ECG screen Day 1 ( predose ) first treatment period Electrolyte abnormality ( hypokalemia , hypocalcemia , hypomagnesemia ) , grade 2 great , within 21 day prior intake investigational medication History galactose intolerance , lactase deficiency glucosegalactose malabsorption Use concomitant medication , include overthecounter product dietary supplement Systemic overthecounter medication must discontinue least 7 day prior first dose study medication prescribe medication product contain Hypericum perforatum ( e.g . St. John 's wort ) must discontinue least 14 day first dose study medication , except paracetamol Participation investigational drug trial within 60 day prior first intake trial medication Donation blood plasma within 60 day precede first drug intake Having participate 1 trial TMC125 ( etravirine ) , TMC120 ( dapirivine ) and/or TMC278 ( rilpivirine , formerly know R278474 ) develop rash , erythema urticaria participate trial aforementioned compound Subjects laboratory abnormality screen defined Division AIDS accordance normal range clinical laboratory .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>TMC125-C187</keyword>
	<keyword>TMC125-TiDP2-C187</keyword>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>Fungal Infection</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>